RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus - Scorecard - MDSpire

RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

Positive clinical data shows improvement in visual function in patients with infantile nystagmus

  • By

  • Conexiant News Staff

  • January 13, 2026

  • 1 min

Share

Clinical Scorecard: RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

At a Glance

CategoryDetail
ConditionInfantile Nystagmus
Key MechanismsNeuroplasticity-based visual training
Target PopulationPatients with congenital eye movement disorder
Care SettingOphthalmology

Key Highlights

  • First randomized controlled evidence for RevitalVision's efficacy
  • Improvement in visual function reported
  • FDA-cleared digital therapeutic treatment

Guideline-Based Recommendations

Diagnosis

  • Clinical evaluation of eye movement patterns
  • Assessment of visual function

Management

  • Consider RevitalVision as a treatment option for infantile nystagmus

Monitoring & Follow-up

  • Regular follow-up to assess visual function improvement

Risks

  • Potential variability in treatment response among patients

Patient & Prescribing Data

Infants and children with infantile nystagmus

Digital therapeutic may enhance visual outcomes

Clinical Best Practices

  • Incorporate neuroplasticity-based therapies in treatment plans
  • Monitor patient progress with standardized visual function assessments

Related Resources & Content

Original Source(s)

RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

  • by Conexiant News Staff

  • January 13, 2026

Related Content

Multimodal human–computer interaction in interventional radiology and surgery: a systematic literature review

AI Supports Glaucoma Surgical Planning

Predictive models identify high-risk patients and support earlier treatment decisions.

Fostering an Interventional Glaucoma Culture

A practice administrator shares tips for reducing barriers to treatment.